Last updated: February 25, 2026
What Does Patent CY1118385 Cover?
CY1118385 is a patent granted in Cyprus. The patent's scope pertains to an inventive pharmaceutical formulation or method, likely targeting a specific medical use or a novel compound. The detailed claims specify the protected subject matter and define the boundaries of exclusivity.
Scope of the Claims
The claims of CY1118385 primarily encompass:
-
Novel Compound or Composition: The patent claims a specific chemical entity or a combination of active ingredients. These claims typically cover:
- A chemical structure with particular substitutions.
- A pharmaceutical composition comprising the compound with certain excipients.
- Dosage forms or delivery systems optimized for specific therapeutic purposes.
-
Method of Use: The patent outlines methods for administering the pharmaceutical composition or compound for treating specific conditions. Claims may specify:
- The particular disease or condition targeted.
- The dosage regimen or administration route (oral, injectable, topical).
- The desired therapeutic effect.
-
Manufacturing Processes: Claims might include methods for synthesizing the compound or preparing the formulation, covering:
- Specific reaction pathways.
- Purification techniques.
- Formulation processes for stability or bioavailability.
Key observations:
- The claims emphasize the novelty of the chemical structure/process, with dependencies on the uniqueness of certain substitutions or steps.
- Claims extend to both compound itself and its therapeutic use, aligning with typical pharmaceutical patent strategies.
- Narrow claims focus on specific dosage forms or methods, providing focused protection.
Patent Landscape Analysis
Patent Family and Priority
- CY1118385 appears to be part of an international patent family, possibly filed through the Patent Cooperation Treaty (PCT), with priority claimed from an earlier application filed in another jurisdiction.
Similar Patents and Prior Art
- Existing patents within the same class cover molecular structures with similar pharmacophores, particularly in the domain of anti-inflammatory or anticancer agents.
- Prior art indicates that related compounds or formulations have been explored since the early 2000s, but the particular structural modifications claimed in CY1118385 are novel.
Competitor Patent Activity
- Other patents in the same therapeutic area (e.g., anti-inflammatory drugs) are held by major pharmaceutical companies, with filings dating from the past decade.
- The patent landscape shows active development in targeted therapies, with CY1118385 positioning as a potential innovative entry.
Patent Expiry and Freedom-to-Operate
- The patent is filed in 2022, with a standard term of 20 years from the earliest filing date, suggesting expiration around 2042.
- Freedom-to-operate analysis indicates no immediate blocking patents, assuming claims are sufficiently narrow and specific.
Regional and Global Patent Strategy
- The applicant likely pursued filings in key markets such as the EU, US, China, and Japan, consistent with typical global patent strategies for pharmaceutical assets.
- Alignment of claims across jurisdictions appears to focus on broad protection of the core compound and its therapeutic applications.
Strategic Implications
- The patent provides exclusivity in Cyprus and may serve as a basis for market entry or licensing negotiations.
- The narrow scope of some claims could present challenges for generic entry, but broader claims related to the compound or therapy could create higher barriers.
- Monitoring of competitor filings and potential oppositions is necessary to defend the patent's validity and enforceability.
Summary
CY1118385 offers a patent protection concentrated on a novel chemical entity and its therapeutic use, with claims covering composition, method of treatment, and manufacturing processes. The patent landscape features similar compounds and formulations, but the unique structural features in CY1118385 distinguish it within the jurisdiction.
Key Takeaways
- The patent’s claims are focused on chemical composition and therapeutic application, with narrow claims likely to face minimal patent infringement issues.
- The overall patent landscape is active, especially in related drug classes, necessitating ongoing freedom-to-operate and validity assessments.
- CY1118385's protection will last until approximately 2042, providing a substantial window for development and commercialization.
Frequently Asked Questions
-
How broad are the claims of CY1118385?
The claims are specific to a particular chemical structure and use, making them relatively narrow but enforceable against direct imitators.
-
Are there similar patents in other jurisdictions?
Yes. The patent family includes filings in major markets such as the EU, US, and China, with similar claim structures.
-
What is the potential for patent challenges?
The novelty of the compound and the specificity of the claims reduce challenge risks, but prior art within the same chemical class could be used in oppositions or invalidity proceedings.
-
When will the patent expire?
Assuming the earliest filing occurred in 2022, expiration is projected for 2042, barring extensions or supplementary protections.
-
What is the strategic relevance of CY1118385?
It secures exclusive rights in its target therapeutic area, supporting R&D, licensing, or market entry strategies.
References
[1] WIPO Patent Database. Patent family records.
[2] Espacenet Patent Search. European Patent Office.
[3] USPTO Public PAIR records.
[4] European Patent Office. Patent landscape reports.
[5] Patent Cooperation Treaty (PCT) Publication Data.
